WO2002068391A8 - Process for resolving racemic mixtures of piperidine derivatives - Google Patents

Process for resolving racemic mixtures of piperidine derivatives

Info

Publication number
WO2002068391A8
WO2002068391A8 PCT/US2001/042934 US0142934W WO02068391A8 WO 2002068391 A8 WO2002068391 A8 WO 2002068391A8 US 0142934 W US0142934 W US 0142934W WO 02068391 A8 WO02068391 A8 WO 02068391A8
Authority
WO
WIPO (PCT)
Prior art keywords
resolving
resolving agent
racemic mixtures
piperidine derivatives
enantiomer
Prior art date
Application number
PCT/US2001/042934
Other languages
French (fr)
Other versions
WO2002068391A1 (en
Inventor
Eric David Moher
Allie Edward Tripp
Original Assignee
Lilly Co Eli
Eric David Moher
Allie Edward Tripp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli, Eric David Moher, Allie Edward Tripp filed Critical Lilly Co Eli
Priority to EP01273837A priority Critical patent/EP1341762A1/en
Priority to AU2001297647A priority patent/AU2001297647A1/en
Priority to US10/415,758 priority patent/US20040039206A1/en
Publication of WO2002068391A1 publication Critical patent/WO2002068391A1/en
Publication of WO2002068391A8 publication Critical patent/WO2002068391A8/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

A process for resolving a racemic mixture into its (R) and (S) enantiomers. The racemic mixture is reacted with a resolving agent selected from the group consisting of di-benzoyl-L-tartaric acid, di-benzoyl-D-tartaric acid, (S)-mandelic acid and (R)-mandelic acid in a solvent. The reaction is carried out under conditions sufficient to form soluble diastereomeric salts comprising the (R) enantiomer and the resolving agent, and the (S) enantiomer and the resolving agent, respectively. One of the diastereomeric salts is then isolated from the mixture. The free base of the isolated salt may then be generated in situ, and directly reacted with other compounds to synthesize useful chiral compounds.
PCT/US2001/042934 2000-11-20 2001-11-13 Process for resolving racemic mixtures of piperidine derivatives WO2002068391A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP01273837A EP1341762A1 (en) 2000-11-20 2001-11-13 Process for resolving racemic mixtures of piperidine derivatives
AU2001297647A AU2001297647A1 (en) 2000-11-20 2001-11-13 Process for resolving racemic mixtures of piperidine derivatives
US10/415,758 US20040039206A1 (en) 2001-11-13 2001-11-13 Process for resolving racemic mixtures of piperidine derivatives

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24997100P 2000-11-20 2000-11-20
US60/249,971 2000-11-20

Publications (2)

Publication Number Publication Date
WO2002068391A1 WO2002068391A1 (en) 2002-09-06
WO2002068391A8 true WO2002068391A8 (en) 2003-12-11

Family

ID=22945777

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/042934 WO2002068391A1 (en) 2000-11-20 2001-11-13 Process for resolving racemic mixtures of piperidine derivatives

Country Status (3)

Country Link
EP (1) EP1341762A1 (en)
AU (1) AU2001297647A1 (en)
WO (1) WO2002068391A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6664271B1 (en) * 1999-05-21 2003-12-16 Eli Lilly And Company Immunopotentiator agents
SE0303220D0 (en) 2003-11-28 2003-11-28 Astrazeneca Ab New process
CN105102430A (en) 2013-02-20 2015-11-25 罗伊特化学仪器制造两合公司 Process for the preparation of enantiomerically enriched 3-aminopiperidine
US20160068486A1 (en) 2013-04-22 2016-03-10 Reuter Chemische Apparatebau Kg Process for preparing enantiomerically enriched 3-hydroxymethylpiperidine
CN109761886B (en) * 2019-02-21 2020-09-11 北京悦康科创医药科技股份有限公司 Resolution method of argatroban starting material isomer impurities

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6664271B1 (en) * 1999-05-21 2003-12-16 Eli Lilly And Company Immunopotentiator agents

Also Published As

Publication number Publication date
AU2001297647A1 (en) 2002-09-12
EP1341762A1 (en) 2003-09-10
WO2002068391A1 (en) 2002-09-06

Similar Documents

Publication Publication Date Title
CA2200490C (en) Racemisation and asymmetric transformation processes used in the manufacture of levobupivacaine and analogues thereof
AP1859A (en) Chiral salt resolution.
BR0316902A (en) Processes for preparing (+) duloxetine and (+) duloxetine hydrochloride, chiral acid salt and (+) duloxetine, (+) duloxetine di-p-toluyl tartrate, (+) duloxetine and pharmaceutical composition
WO2004035575A8 (en) Process for the preparation of (s,s)-cis-2-benzhydryl-3-benzylaminoquinuclidine
CA2272716A1 (en) Resolution of ritalinic acid salt
Alcaide et al. A Novel One‐Step Approach for the Preparation of α‐Amino Acids, α‐Amino Amides, and Dipeptides from Azetidine‐2, 3‐diones
DE60014542D1 (en) A METHOD FOR THE PRODUCTION OF CARBONIC ACID DERIVATIVES AND A CONDENSATION TOOL WITH A QUARTERARY AMMONIUM SALT
WO2002068391A8 (en) Process for resolving racemic mixtures of piperidine derivatives
PL184091B1 (en) Racemisation proces for use in production of levobupivacaine and other piperidinocaboxyanilide anasethetic agents showing affinity thereto
AU6262990A (en) Process for the chemical resolution of 5-alkoxy-substituted (+ or -)-1,3-dimethyloxindolylethylamines
RU1836371C (en) Method for obtaining derivatives of 5,5a,6,7,8,9,9a,10-octahydropyrido(2,3- )-quinoline or their pharmaceutically acceptable salts
US5821369A (en) Racemisation process
CA2445207A1 (en) Process for the preparation of 2-[5-(4-fluorophenyl)-3-pyridylmethylaminomethyl]chroman
Zhenghong et al. Synthesis of optically active α, β-unsaturated triazolyl alcohols via chiral auxiliary-modified NaBH4 reduction of the corresponding ketones
CA2339826A1 (en) Process for the production of n-protected azetidine-2-carboxylic acids (azeohs)
HU9202806D0 (en) Method for separing enenthiomers of 5-hetaryl-1,3,4-thiadiazinone derivatives
CA2197900A1 (en) Racemization of optically active amines
ATE212615T1 (en) METHOD FOR PRODUCING (1S,2R)-1-AMINO-2-INDANOL-(R,R)-TARTRATE METHANOL SOLVATE
ATE288439T1 (en) METHOD FOR PRODUCING FORMYLPHENYLBORONIC ACIDS
CA2284976A1 (en) Process for preparing single enantiomer narwedine
CA2384925A1 (en) Process for the preparation of oxazole derivatives
DE60219837D1 (en) CRYSTALLINE FORM OF QUINAPRIL HYDROCHLORIDE AND METHOD FOR THE PRODUCTION THEREOF
JPH11510471A (en) Racemization of levobupivacaine and its precursors

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 10415758

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2001273837

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2001273837

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i

Free format text: IN PCT GAZETTE 36/2002 DUE TO A TECHNICAL PROBLEM AT THE TIME OF INTERNATIONAL PUBLICATION, SOME INFORMATION WAS MISSING (81). THE MISSING INFORMATION NOW APPEARS IN THE CORRECTED VERSION

WWW Wipo information: withdrawn in national office

Ref document number: 2001273837

Country of ref document: EP

NENP Non-entry into the national phase in:

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP